Commonly reported side effects of valganciclovir include: anemia and neutropenia. Other side effects include: thrombocytopenia.  See below for a comprehensive list of adverse effects.
Applies to valganciclovir: oral powder for solution, oral tablet
As well as its needed effects, valganciclovir may cause unwanted side effects that require medical attention. 
If any of the following side effects occur while taking valganciclovir, check with your doctor immediately:
Some valganciclovir side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:


Applies to valganciclovir: oral powder for reconstitution, oral tablet
After oral administration, this drug is rapidly converted to ganciclovir.  Therefore, side effects that are known to be associated with ganciclovir administration can be expected to occur with this drug.  The most common side effects reported with this drug were diarrhea, pyrexia, nausea, tremor, neutropenia, anemia, graft rejection, thrombocytopenia, and vomiting.[Ref]
Very common (10% or more): Diarrhea (up to 41%), nausea (up to 30%), vomiting (up to 21%), oral candidiasis (up to 20%), constipation (up to 20%), abdominal pain (up to 15%), dyspepsia (up to 12%)Common (1% to 10%): Upper abdominal pain, abdominal distention, ascites, flatulence, dysphagiaUncommon (0.1% to 1%): Mouth ulceration, pancreatitisGanciclovir:-Frequency not reported: Abdominal distension, ascites, cholangitis, dry mouth, dyspepsia, dysphagia, eructation, esophagitis, fecal incontinence, flatulence, gastritis, gastrointestinal disorder, gastrointestinal hemorrhage, mouth ulceration, pancreatitis, tongue disorder[Ref]
Very common (10% or more): Anemia (up to 31%), neutropenia (including severe; up to 24%), thrombocytopenia (up to 22%), leukopenia (up to 20%)Common (1% to 10%): Severe anemia, severe thrombocytopenia, severe leukopenia, pancytopenia (including severe)Uncommon (0.1% to 1%): Bone marrow failure/depressionRare (less than 0.1%): Aplastic anemiaFrequency not reported: Potentially life-threatening bleeding associated with thrombocytopenia, febrile neutropenia, neutrophil dysplasia with evidence of bone marrow hypoplasiaGanciclovir:-Frequency not reported: Eosinophilia, leukocytosis, lymphadenopathy, splenomegaly[Ref]
Neutropenia (absolute neutrophil count [ANC] less than 500/mcL: up to 19%; ANC 500 to less than 750/mcL: up to 17%; ANC 750 to less than 1000/mcL: up to 17%), anemia (hemoglobin [Hgb] less than 8 g/dL: up to 8%; Hgb less than 6.5 g/dL: up to 7%; Hgb 6.5 to less than 8 g/dL: up to 13%; Hgb 8 to less than 9.5 g/dL: up to 31%), and thrombocytopenia (less than 25,000 platelets/mcL: up to 4%; 25,000 to less than 50,000 platelets/mcL: up to 6%; 50,000 to less than 100,000 platelets/mcL: up to 22%) have been reported.[Ref]
Very common (10% or more): Pyrexia (up to 31%), lower limb edema (up to 21%), fatigue (up to 20%), peripheral edema (up to 18%), postoperative pain (up to 13%), postoperative complications (up to 12%), CMV infection (up to 12%), edema (up to 11%), postoperative wound infection (up to 11%)Common (1% to 10%): Catheter-related infections, pain, weakness, sepsis (bacteremia, viremia), decreased weight, increased wound drainage, wound dehiscence, CMV syndrome, ear pain, chills, chest pain, malaise, astheniaFrequency not reported: Local and systemic infectionsGanciclovir:-Frequency not reported: Asthenia, infections (bacterial, fungal, viral), malaise, mucous membrane disorder, pain, rigors, sepsis, decreased libido, edema, earache[Ref]
Very common (10% or more): Tremors (up to 28%), headache (up to 22%)Common (1% to 10%): Peripheral neuropathy, paresthesia, dizziness (excluding vertigo), dysgeusia, hypoesthesia, convulsionUncommon (0.1% to 1%): DeafnessFrequency not reported: NeurotoxicityGanciclovir:-Frequency not reported: Amnesia, ataxia, coma, hypertonia, myasthenic syndrome, migraine, myoclonic jerks, somnolence, tremor, taste disturbance, deafness, tinnitus[Ref]
Very common (10% or more): Graft/transplant rejection (up to 24%)[Ref]
Very common (10% or more): Insomnia (up to 20%)Common (1% to 10%): Depression, anxiety, confusion, abnormal thinkingUncommon (0.1% to 1%): Psychotic disorder, hallucinations, agitationGanciclovir:-Frequency not reported: Abnormal thinking, abnormal dreams, anxiety, decreased libido, emotional disturbance, hyperkinetic syndrome, nervousness[Ref]
Very common (10% or more): Back pain (up to 20%)Common (1% to 10%): Arthralgia, muscle cramps/spasms, limb pain, myalgiaGanciclovir:-Frequency not reported: Musculoskeletal pain, increased blood creatine phosphokinase[Ref]
Very common (10% or more): Urinary tract infection (up to 19%)Common (1% to 10%): Dysuria, hematuriaUncommon (0.1% to 1%): Male infertilityPostmarketing reports: Decreased fertility in malesGanciclovir:-Frequency not reported: Hematuria present, impotence, urinary frequency[Ref]
Very common (10% or more): Hypertension (up to 18%)Common (1% to 10%): HypotensionUncommon (0.1% to 1%): ArrhythmiaGanciclovir:-Frequency not reported: Arrhythmia (including ventricular arrhythmia), deep thrombophlebitis, hemorrhage, hypertension, hypotension, phlebitis, tachycardia, vasodilatation[Ref]
Very common (10% or more): Dermatitis (up to 18%)Common (1% to 10%): Night sweats, pruritus, acne, cellulitisUncommon (0.1% to 1%): Alopecia, urticaria, dry skinGanciclovir:-Frequency not reported: Acne, alopecia, exfoliative dermatitis, dry skin, increased sweating, urticaria, photosensitivity reaction[Ref]
Very common (10% or more): Elevated serum creatinine (up to 50%)Common (1% to 10%): Renal impairment, decreased CrClUncommon (0.1% to 1%): Renal failureFrequency not reported: Acute renal failureGanciclovir:-Frequency not reported: Renal failure[Ref]
Elevated serum creatinine (greater than 2.5 mg/dL: up to 17%; greater than 1.5 to 2.5 mg/dL: up to 50%) has been reported.[Ref]
Very common (10% or more): Cough (up to 16%), pharyngitis/nasopharyngitis (up to 12%), dyspnea (up to 11%)Common (1% to 10%): Productive cough, rhinorrhea, pleural effusion, sinusitis, upper respiratory tract infection, influenza, pneumonia, bronchitis, Pneumocystis carinii pneumoniaGanciclovir:-Frequency not reported: Pleural effusion, sinus congestion[Ref]
Very common (10% or more): Retinal detachment (up to 15%)Common (1% to 10%): Blurred vision, macular edema, vitreous floaters, eye painUncommon (0.1% to 1%): Visual disturbance, conjunctivitisGanciclovir:-Frequency not reported: Amblyopia, blindness, eye hemorrhage, eye pain, glaucoma, abnormal vision, vitreous disorder[Ref]
Very common (10% or more): Hyperkalemia (up to 14%), hypophosphatemia (up to 12%)Common (1% to 10%): Anorexia, cachexia, hypokalemia, hypomagnesemia, hyperglycemia, decreased appetite, dehydration, hypocalcemia, increased blood alkaline phosphataseGanciclovir:-Frequency not reported: Increased blood alkaline phosphatase, decreased blood glucose, increased blood lactic dehydrogenase, decreased blood magnesium, diabetes mellitus, hypocalcemia, hypokalemia, hypoproteinemia[Ref]
Common (1% to 10%): Abnormal hepatic function (including severe), increased ASTUncommon (0.1% to 1%): Increased ALTGanciclovir:-Frequency not reported: Hepatitis, jaundice, abnormal hepatic function[Ref]
Uncommon (0.1% to 1%): Anaphylactic reactionFrequency not reported: Valganciclovir hypersensitivityPostmarketing reports: Anaphylaxis[Ref]
1. "Product Information. Valcyte (valganciclovir)" Roche Laboratories, Nutley, NJ. 
2. "Oral prodrug of ganciclovir for CMV retinitis." Am J Health Syst Pharm 58 (2001): 946-8
3. Cerner Multum,  Inc. "Australian Product Information." O 0
4. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0
5. Cvetkovic RS,  Wellington K "Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients." Drugs 65 (2005): 859-78
6. Segarra-Newnham M,  Salazar MI "Valganciclovir: A new oral alternative for cytomegalovirus retinitis in human immunodeficiency virus-seropositive individuals." Pharmacotherapy 22 (2002): 1124-8
7. Curran M, Noble S "Valganciclovir." Drugs 61 (2001): 1145-50
8. Babel N,  Gabdrakhmanova L,  Juergensen JS, et al. "Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: a single center experience." Transplantation 78 (2004): 283-5
9. Gabardi S,  Magee CC,  Baroletti SA,  Powelson JA,  Cina JL,  Chandraker AK "Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis." Pharmacotherapy 24 (2004): 1323-30
10. Ayala E,  Greene J,  Sandin R, et al. "Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation." Bone Marrow Transplant 37 (2006): 851-6
11. Wang TJ,  Lin CP,  Yang CM,  Lin LL "Valgancyclovir as maintenance therapy for cytomegalovirus retinitis in a lung transplant patient-a case report." Transplant Proc 36 (2004): 2826-9
12. Diaz-Pedroche C,  Lumbreras C,  San Juan R, et al. "Valganciclovir Preemptive Therapy for the Prevention of Cytomegalovirus Disease in High-Risk Seropositive Solid-Organ Transplant Recipients." Transplantation 82 (2006): 30-35
13. Molina Perez E,  Fernandez Castroagudin J,  Seijo Rios S, et al. "Valganciclovir-induced leukopenia in liver transplant recipients: influence of concomitant use of mycophenolate mofetil." Transplant Proc 41 (2009): 1047-9
14. Brum S,  Nolasco F,  Sousa J, et al. "Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil." Transplant Proc 40 (2008): 752-4
15. "Agranulocytosis in kidney transplant recipients receiving tacrolimus, mycophenolate mofetil and valganciclovir." Transplantation 82(1 Suppl 2) (2006): 952
16. Taegtmeyer AB,  Halil O,  Bell AD,  Carby M,  Cummins D,  Banner NR "Neutrophil dysplasia (acquired pseudo-pelger anomaly) caused by ganciclovir." Transplantation 80 (2005): 127-30
17. "Efficacy and safety of CMV prophylaxis with valganciclovir 900 mg/day for 100 days versus 450 mg/day for 6 months post-renal transplantation." Transplantation 82(1 Suppl 2) (2006): 585
18. Humar A,  Siegal D,  Moussa G,  Kumar D "A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients." J Infect Dis 192 (2005): 1154-7
19. Keven K,  Basu A,  Tan HP, et al. "Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning." Transplant Proc 36 (2004): 3107-12
20. Dupuis R,  Harris M,  Gillis K, et al. "Experience with low-dose valganciclovir prophylaxis in adult liver transplant recipients." Transplant Proc 39 (2007): 3266-70
21. Said T,  Nampoory MR,  Pacsa AS, et al. "Oral valgancyclovir versus intravenous gancyclovir for cytomegalovirus prophylaxis in kidney transplant recipients." Transplant Proc 39 (2007): 997-9
22. Cochrane AB "Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients." Am J Health Syst Pharm 63(19 Suppl 5) (2006): S17-21
23. "Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients." Transplantation 82(1 Suppl 2) (2006): 266-7
24. Czock D,  Scholle C,  Rasche FM,  Schaarschmidt D,  Keller F "Pharmacokinetics of valganciclovir and ganciclovir in renal impairment." Clin Pharmacol Ther 72 (2002): 142-150
25. Wiltshire H,  Paya CV,  Pescovitz MD, et al. "Pharmacodynamics of Oral Ganciclovir and Valganciclovir in Solid Organ Transplant Recipients." Transplantation 79 (2005): 1477-1483
26. Fellay J,  Venetz JP,  Aubert JD,  Seydoux C,  Pascual M,  Meylan PR "Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir." Transplant Proc 37 (2005): 949-51
27. Pescovitz MD,  Jain A,  Robson R,  Mulgaonkar S,  Freeman R,  Bouw MR "Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation." Transplant Proc 39 (2007): 3111-6
It is possible that some side effects of valganciclovir may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

Black, tarry stools
blood in the urine or stools
blurred vision
chills
cough
dizziness
fever
headache
hoarseness
lower back or side pain
nervousness
painful or difficult urination
pale skin
pinpoint red spots on the skin
pounding in the ears
seeing flashes or sparks of light
seeing floating spots before the eyes
shakiness in the legs, arms, hands, or feet
shortness of breath
slow or fast heartbeat
sore throat
trembling or shaking of the hands or feet
troubled breathing
troubled breathing with exertion
ulcers, sores, or white spots in the mouth
unusual bleeding or bruising
unusual tiredness or weakness
veil or curtain appearing across part of vision


Changes in facial skin color
confusion
false beliefs
fast or irregular breathing
feeling, hearing, or seeing things that are not there
hives, itching, and skin rash
large, hive-like swellings on the eyelids, face, lips, mouth, or tongue
puffiness or swelling of the eyelids or around the eyes
runny or stuffy nose
seizures
tightness in the chest
trouble thinking


Abdominal or stomach pain
diarrhea
headache
nausea and vomiting
numbness, tingling, pain, or weakness of the hands or feet
sleeplessness
tingling, burning, or prickly sensations
trouble with sleeping
unsteadiness or awkwardness


Agitation

